sarcoma

This page shows the latest sarcoma news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca expands alliance with Bicycle Therapeutics

The peptide portion of BT1718 binds to MT1-MMP, which is highly expressed in many solid tumours, including triple negative breast cancer, sarcoma and non-small cell lung cancer, and is

Latest news

Merck forges closer ties with Cancer Research UK

notable pipeline failures, including evofosfamide for advanced soft tissue sarcoma and pancreatic cancer.
Bayer gets clinical data to support $1.5bn Loxo deal

uncontrolled cellular growth that is evident in a wide range of tumours, including infantile fibrosarcoma, thyroid cancer and various soft tissue sarcomas, but collectively account for less than 1% of all
Loxo’s cancer drug pair attracts $1.5bn deal with Bayer

They are seen in a collection of malignancies including colorectal adenocarcinoma, soft tissue sarcoma, infantile fibrosarcoma and cholangiocarcinoma.
Avelumab costs peg back profit at Merck KGaA

sarcoma and pancreatic cancer after phase III study failures.
Merck's pharma unit faces tougher 2017 as fertility boost recedes

Last year, Merck abandoned plans to seek approval of evofosfamide in advanced soft tissue sarcoma and pancreatic cancer after phase III study failures.

More from news
Approximately 6 fully matching, plus 48 partially matching documents found.

Latest Intelligence

Europe vs the US: New drug product approvals

Among the noteworthy approvals are Lartruvo (for the treatment of soft tissue sarcoma, approved in the EU and US), Rubraca (for the treatment of ovarian cancer, only approved in the US),
Case study: Treatment guidance

The Practical Guide was launched as part of a Takeda sponsored symposium at the British Sarcoma Group’ s annual conference.
Case study: Treatment guidance

The Practical Guide was launched as part of a Takeda sponsored symposium at the British Sarcoma Group’ s annual conference.
Pharma deals during February 2014

for advanced sarcoma.
Interview: Harvey Berger and Timothy Clackson, Ariad

And that was absolutely correct.”. After selling off investigational sarcoma treatment ridaforolimus to Merck &Co following an aborted collaboration attempt, ponatinib emerged as the front-runner in the company's pipeline

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Client Services Director – Healthcare Advertising - London: Neg

Account Director, Consumer Healthcare PR, Global PR agency: £50, 000 – £58, 000

Business Unit Head, Medical Communications, London: Excellent package

Account Director, Medical Communications: C£50 – 65, 000 benefits and bonus

Home based, Senior Medical Writer, Medical Communications: Excellent package

Editorial Director – Medical Education (MedComms): Neg

Delivery Manager/ Head of Delivery – Executive Search: Neg

Healthcare PR Director: £100, 000 – £120, 000 benefits

Scientific Communications Director - Oncology – In House Pharma ...: Neg

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Senior Medical Writer, Healthcare Advertising Agency: £45, 000 – £50, 000

Client Services Director - Med Comms: Great salary and bebefits

Home based, Chief Medical Writer, Medical Communications: Excellent package

Account Manager: £40, 000 - £45, 000 benefits

Senior Account Manager: Competitive salary commensurate with experience

Senior Project Manager - Medical Writing: Great salary and bebefits

Home based, Principal Medical Writer, Medical Communications: Excellent package

Strategic Planner, Healthcare Advertising: £47, 000 – £53, 000

Home based, Editorial Team Leader, Medical Communications: Excellent package

Subscribe to our email news alerts

PMHub

Add my company

Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

Developing advocacy in the pharmaceutical industry.: The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?: Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?: The modern approach to B2B sales is data-driven, and enabled by digital tools....